CORE--RADIOPHARMACY

核心B（放射性药物学）的主要目标是为以下方面提供支持 项目1，人类研究。 钇-90放射性标记的嵌合T84.66抗- CEA抗体将用于I期和II期临床试验， 结肠癌和乳腺癌患者在希望之城国家医疗中心 中心 铟-111放射性标记的嵌合T84.66抗体将用于 剂量测定目的。 碘-123标记的嵌合T84.66片段 将用于I期成像研究。 放射性药物将支持 项目1：提供专门知识和设施， 抗体，并为这些试剂提供质量控制。 的协议 用于In-111、Y-90和I-123标记单克隆抗体的大规模制备 抗体目前处于活跃状态。 作为其核心活动的一部分， 放射性药物学也支持单克隆抗体的偶联 用于临床试验的构建体。 核心B的次要目的是为临床 开发新的构建体和螯合物。 这样，核心 支持项目2（生物工程抗体）和项目3（抗体 螯合物和缀合物）。 生化和放射稳定性 将确定这些抗体制备物， 提交IND申请的信息。

The primary objective of Core B (Radiopharmacy) is to provide support to Project 1, Human Studies. Yttrium-90 radiolabeled chimeric T84.66 anti- CEA antibody will be used in Phase I and Phase II clinical trials for colon and breast cancer patients at the City of Hope National Medical Center. Indium-111 radiolabeled chimeric T84.66 antibody will be used for dosimetry purposes. iodine-1`23 rabiolabeled chimeric T84.66 fragments will be used for Phase I imaging studies. The radiopharmacy will support Project 1 by providing expertise and facilities to prepare radiolabeled antibodies and to provide quality control for these reagents. A protocol for large-scale preparation of In-111, Y-90 and I-123 labeled monoclonal antibodies is currently active. As part of its core activity the Radiopharmacy also supports the conjugation of the monoclonal antibody constructs to be used in the clinical trials. The secondary objective of Core B is to provide labeling for clinical development of novel constructs and chelates. In this way, the Core supports project 2 (Bioengineered Antibodies) and Project 3 (Antibody Chelates and Conjugates). The biochemical and radiological stabilities will be determined for these antibody preparations, providing this information for the filing of IND applications.